Advanced Biomed Inc. (ADVB)
ADVB trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/0001213900-26-109029-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | ADVB on Nasdaq |
| Sector | Health Care |
| Industry | Medical Specialities |
| Country | Taiwan |
| IPO year | 2025 |
| SEC CIK | 0001941029 |
| SEC industry code | Services-Medical Laboratories |
| Incorporated in | NV |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $128K |
| Net income | $6.7M |
| Operating income | -$6.2M |
| Net margin | 5231.3% |
| Operating margin | -4883.8% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $386K |
| Total assets | $13.8M |
| P/E (computed) | 0.5× |
| P/S (computed) | 28.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $214K cash; operating cash flow -$377K a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,652,133 (2026-11-12); 21,640,000 a year earlier. 1y figure adjusted for split (1-for-20 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-02-20 | Source 2026-02-20 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-21 |
| Auditor | WWC, P.C., San Mateo, California, United States | PCAOB Form AP 2026-10-15 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-09-28 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | Not filed | -$989K | -$171K | $214K | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2026 2026-06-30 | Not filed | $695K | -$583K | $386K | No debt tags | $128K | 10-K 2026-10-13 |
| Q3 2026 2026-03-31 | Not filed | -$489K | -$240K | $2.6M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q2 2026 2025-12-31 | Not filed | $6.9M | -$514K | $2.6M | No debt tags | Needs four quarters | 10-Q 2026-02-13 |
| Q1 2026 2025-09-30 | Not filed | -$387K | -$610K | $13K | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-06-30 | Not filed | -$702K | -$1.5M | $31K | No debt tags | Needs four quarters | 10-K 2026-10-13 |
| Q3 2025 2025-03-31 | Not filed | -$1.4M | -$3.4M | $3.2M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q2 2025 2024-12-31 | Not filed | -$908K | -$842K | $2.6M | No debt tags | Needs four quarters | 10-Q 2026-02-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-1 | 2025-07-23 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-10-13 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-07-17 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-06-04 |
Source: SEC EDGAR submissions feed, 99 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +27.8% |
| 1 month | -51.0% |
| 3 months | -70.5% |
| Year to date | -56.7% |
| 1 year | -71.8% |
| From 52-week high | -86.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical Specialities
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACON | Aclarion Inc. | $1.39 | -12.58% | $4.0M |
| BGLC | BioNexus Gene Lab Corp | $0.8200 | -0.12% | $2.4M |
| ACH | Accendra Health Inc. | $0.0857 | -35.08% | $6.6M |
| AMS | American Shared Hospital Services | $1.07 | -0.93% | $7.1M |
| MDXH | MDxHealth SA | $0.1490 | +3.40% | $14.2M |
| SERA | Sera Prognostics Inc. | $1.94 | -3.48% | $77.2M |
| XGN | Exagen Inc. | $3.77 | -8.72% | $96.2M |
| BDSX | Biodesix Inc. | $9.00 | -8.91% | $99.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier